FcRH2 Inhibitors
Fc Receptor Homolog 2 (FcRH2) is an immunoregulatory protein expressed primarily on B cells and is considered significant in the modulation of immune responses. The expression of FcRH2 is an intricate process, influenced by a myriad of factors including cellular signaling pathways, transcriptional machinery, and the chromatin state within the cell nucleus. Understanding the regulation of FcRH2 is of interest in the field of immunology, as its expression is a reflection of the dynamic state of B cells within the immune system. The modulation of FcRH2 expression can have profound effects on the functional characteristics of B cells, including their proliferation, differentiation, and antibody production.
The potential inhibition of FcRH2 expression can be achieved through the use of various chemicals that target distinct aspects of the cellular machinery. For instance, compounds such as 5-Azacytidine and Trichostatin A are known to induce epigenetic modifications. 5-Azacytidine can cause the demethylation of DNA, potentially leading to the downregulation of gene transcription, whereas Trichostatin A can increase histone acetylation, resulting in a more restrictive chromatin structure that could hinder the transcription of certain genes. On a different front, chemicals like Sirolimus, also known as Rapamycin, target cellular signaling pathways, specifically the mTOR pathway, which plays a critical role in cell cycle progression. By stalling cells in the G1 phase, Sirolimus can decrease the transcriptional activity of genes that are typically upregulated upon B cell activation, which may include FcRH2. Additionally, Chloroquine, which is known to alter endosomal pH, could disrupt antigen processing, leading to attenuated B cell stimulation and potentially diminished FcRH2 expression. The proteasome inhibitor Bortezomib may also play a role in this regard by preventing the degradation of proteins that negatively regulate gene transcription, thereby promoting a decrease in FcRH2 expression. Each of these chemicals operates via a unique mechanism, but collectively they represent the diverse strategies by which the expression of FcRH2 could potentially be inhibited, delineating the complex interplay of cellular processes that govern gene expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could demethylate cytosine bases within the FcRH2 gene promoter, potentially leading to the downregulation of its transcription by creating a less favorable environment for the binding of transcriptional activators. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
By increasing histone acetylation levels, Trichostatin A may cause a loosening of the chromatin structure around the FcRH2 gene locus, potentially decreasing the expression by allowing repressor complexes easier access to DNA. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin might reduce FcRH2 expression by stalling the progression of the G1 phase in the cell cycle, which could decrease the transcriptional activity of genes associated with B cell activation and proliferation, including FcRH2. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine could attenuate the expression of FcRH2 by altering endosomal pH, which might disrupt the processing and presentation of antigens and the consequent stimulation of B cells, leading to a reduced transcriptional activity of activation-induced genes like FcRH2. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib may decrease FcRH2 expression by stabilizing negative regulatory proteins that control transcription, due to inhibition of their proteasomal degradation, thereby promoting a repressive effect on the transcriptional machinery targeting the FcRH2 gene. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate might downregulate FcRH2 expression by disrupting folate metabolism, leading to a depletion of thymidine and a subsequent decrease in DNA synthesis and repair, which could result in decreased expression of proliferation-associated genes, including FcRH2. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide could reduce FcRH2 transcription by altering the balance of pro-inflammatory and anti-inflammatory cytokines, potentially creating an environment that suppresses B cell activation and thus reduces the upregulation of activation-induced genes like FcRH2. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea may downregulate FcRH2 by hindering ribonucleotide reductase, leading to decreased deoxyribonucleotide levels, thus slowing down DNA replication and cell cycle progression, which in turn could decrease the expression of genes involved in cell growth, including FcRH2. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide may decrease expression of FcRH2 by altering the cytokine milieu, leading to a shift in the immune cell interactions and activities that could suppress the conditions favorable for the expression of genes like FcRH2 in B cells. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib could downregulate expression of FcRH2 by blocking the activity of specific tyrosine kinases involved in B cell signaling, resulting in the attenuation of downstream transcriptional events that normally lead to the upregulation of genes such as FcRH2. | ||||||